According to a publication on the ClinicalTrials.gov website operated by the U.S. National Institutes of Health (NIH), two experimental Moderna vaccines, mRNA-1644 and mRNA-1644v2-Core, have passed the phase I testing phase.The randomized trial, conducted for the first time in humans, will enroll about 56 adults aged and over18 to 50 years old. Some of the volunteers are infected with the human immunodeficiency virus. The study is expected to complete around May 2023.
As part of the test, the mRNA-1644 vaccine willapply iterative studies in humans to assess the correctness of the approach, as well as new antigens for immunofocusing. The second drug, mRNA-1574, contains more native trimeric antigens.
Template-based ribonucleic acid vaccinesacids are based on a fundamentally new approach - mRNA preparations contain instructions for the cells of the human body, allowing them to produce certain proteins that provide an immune response.
Moderna achieves great resultsthanks to the success of its mRNA-1273 COVID-19 vaccine, which is projected to sell about $ 20 billion this year. It has also recently begun phase I / II trials of its tetravalent mRNA mRNA-1010 candidate for a seasonal influenza vaccine.
Read more
See the fastest hypersonic aircraft
The slowing down of the Earth's rotation caused the release of oxygen on the planet
What Happens to Cryptocurrency: From Rise and Fall to State Recognition